Last updated on February 2019

[18F]FAraG (VisAcT) PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy

Brief description of study

This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy.

Detailed Study Description

This is an exploratory Phase 1, prospective study assessing the biodistribution and radiation dosimetry of the Positron Emission Tomography [18F]FAraG (VisAcT) in cancer patients selected for immunotherapy. Each patient may have up to two [ 18F]FAraG PET imaging sessions, a baseline image and a post start of immunotherapy image. For each imaging session, patients will receive a single injection of [ 18F]FAraG and undergo up to four whole-body PET scans in the same day. Blood samples may be collected at up to 9 time points post-injection to analyze whole-blood/plasma time activity of [18F]FAraG. Following each imaging session, we will also assess safety in each subject. Blood pressure, heart rate, pulse oximetry, temperature, and respiratory count measurements as well as an electrocardiogram (ECG) recording will be taken prior to imaging, and after whole-body PET scans are completed.

Clinical Study Identifier: NCT03142204

Find a site near you

Start Over

UCSF Imaging Center at China Basin

San Francisco, CA United States
  Connect »